Sangui Biotech International Inc
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and woun… Read more
Sangui Biotech International Inc (SGBI) - Net Assets
Latest net assets as of March 2024: $-1.05 Million USD
Based on the latest financial reports, Sangui Biotech International Inc (SGBI) has net assets worth $-1.05 Million USD as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($89.70K) and total liabilities ($1.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.05 Million |
| % of Total Assets | -1170.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -14364.38% |
| Growth Volatility | 199541.69 |
Sangui Biotech International Inc - Net Assets Trend (2000–2023)
This chart illustrates how Sangui Biotech International Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sangui Biotech International Inc (2000–2023)
The table below shows the annual net assets of Sangui Biotech International Inc from 2000 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-06-30 | $-1.04 Million | -15.97% |
| 2022-06-30 | $-894.96K | -2.24% |
| 2021-06-30 | $-875.33K | -19.93% |
| 2020-06-30 | $-729.88K | -23.29% |
| 2019-06-30 | $-591.99K | -68.59% |
| 2018-06-30 | $-351.14K | -34.78% |
| 2017-06-30 | $-260.52K | -5.23% |
| 2016-06-30 | $-247.57K | +27.15% |
| 2015-06-30 | $-339.83K | -4770.62% |
| 2014-06-30 | $7.28K | -97.54% |
| 2013-06-30 | $296.34K | -69.11% |
| 2012-06-30 | $959.37K | +2445.26% |
| 2011-06-30 | $-40.91K | +86.41% |
| 2010-06-30 | $-301.00K | 0.00% |
| 2009-06-30 | $-301.00K | +72.08% |
| 2008-06-30 | $-1.08 Million | -665711.73% |
| 2007-06-30 | $162.00 | +100.04% |
| 2006-06-30 | $-383.70K | -174.18% |
| 2005-06-30 | $517.29K | 0.00% |
| 2004-06-30 | $517.29K | -75.18% |
| 2003-06-30 | $2.08 Million | -48.73% |
| 2002-06-30 | $4.06 Million | -38.80% |
| 2001-06-30 | $6.64 Million | -28.69% |
| 2000-06-30 | $9.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sangui Biotech International Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3045408100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $33.12 Million | % |
| Other Comprehensive Income | $101.39K | % |
| Other Components | $4.49 Million | % |
| Total Equity | $-382.06K | 100.00% |
Sangui Biotech International Inc Competitors by Market Cap
The table below lists competitors of Sangui Biotech International Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BFNX39
SA:BFNX39
|
$36.51K |
|
Dong Won Fisheries Co. Ltd.
KQ:030720
|
$36.54K |
|
WLMM3F
SA:WLMM3F
|
$36.56K |
|
Canadian Life Companies Split Corp
PINK:CLSPF
|
$36.56K |
|
MTR (MRI.SG)
STU:MRI
|
$36.47K |
|
SIBEK
ST:SIBEK
|
$36.33K |
|
Advantex Marketing International Inc
PINK:ATXMF
|
$36.32K |
|
AGRO3F
SA:AGRO3F
|
$36.32K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sangui Biotech International Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -239,128 to -382,055, a change of -142,927.
- Net loss of 147,721 reduced equity.
- Other comprehensive income increased equity by 4,793.
- Other factors increased equity by 1.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-147.72K | -38.66% |
| Other Comprehensive Income | $4.79K | +1.25% |
| Other Changes | $1.00 | +0.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Sangui Biotech International Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-06-30 | $0.27 | $0.00 | x |
| 2001-06-30 | $0.16 | $0.00 | x |
| 2002-06-30 | $0.10 | $0.00 | x |
| 2003-06-30 | $0.05 | $0.00 | x |
| 2004-06-30 | $0.01 | $0.00 | x |
| 2005-06-30 | $0.01 | $0.00 | x |
| 2006-06-30 | $-0.01 | $0.00 | x |
| 2007-06-30 | $0.00 | $0.00 | x |
| 2008-06-30 | $-0.02 | $0.00 | x |
| 2009-06-30 | $-0.01 | $0.00 | x |
| 2010-06-30 | $-0.01 | $0.00 | x |
| 2011-06-30 | $0.00 | $0.00 | x |
| 2012-06-30 | $0.01 | $0.00 | x |
| 2013-06-30 | $0.01 | $0.00 | x |
| 2014-06-30 | $0.00 | $0.00 | x |
| 2015-06-30 | $0.00 | $0.00 | x |
| 2016-06-30 | $0.00 | $0.00 | x |
| 2017-06-30 | $0.00 | $0.00 | x |
| 2018-06-30 | $0.00 | $0.00 | x |
| 2019-06-30 | $0.00 | $0.00 | x |
| 2020-06-30 | $0.00 | $0.00 | x |
| 2021-06-30 | $0.00 | $0.00 | x |
| 2022-06-30 | $0.00 | $0.00 | x |
| 2023-06-30 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sangui Biotech International Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -158.77%
- • Asset Turnover: 1.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-18311.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -29.52% | -640.43% | 0.04x | 1.04x | $-3.68 Million |
| 2001 | -54.62% | -639.85% | 0.08x | 1.04x | $-4.29 Million |
| 2002 | -118.04% | -839.19% | 0.12x | 1.14x | $-5.20 Million |
| 2003 | -110.90% | 0.00% | 0.00x | 1.06x | $-2.52 Million |
| 2004 | -304.38% | -6778.53% | 0.04x | 1.17x | $-1.63 Million |
| 2005 | -304.38% | -6778.53% | 0.04x | 1.17x | $-1.63 Million |
| 2006 | 0.00% | -532.93% | 1.11x | 0.00x | $-693.12K |
| 2007 | -434945.68% | -1558.46% | 0.27x | 1019.71x | $-704.63K |
| 2008 | 0.00% | -533.85% | 0.17x | 0.00x | $-998.17K |
| 2009 | 0.00% | -7346.10% | 0.32x | 0.00x | $-2.29 Million |
| 2010 | 0.00% | -7346.32% | 0.32x | 0.00x | $-2.29 Million |
| 2011 | -1459.76% | -27449.22% | 0.03x | 1.83x | $-1.54 Million |
| 2012 | -301.53% | -23358.78% | 0.01x | 0.97x | $-3.61 Million |
| 2013 | -315.95% | -1986.50% | 0.20x | 0.79x | $-2.16 Million |
| 2014 | -276.34% | -1070.65% | 0.51x | 0.50x | $-1.48 Million |
| 2015 | -315.00% | -552.84% | 1.04x | 0.55x | $-727.07K |
| 2016 | -124.17% | -879.57% | 0.43x | 0.32x | $-456.28K |
| 2017 | -88.85% | -456.71% | 0.72x | 0.27x | $-343.75K |
| 2018 | -74.44% | -261.57% | 0.76x | 0.38x | $-228.92K |
| 2019 | -643.80% | -359.96% | 1.11x | 1.61x | $-321.69K |
| 2020 | 0.00% | -666.58% | 0.23x | 0.00x | $-184.45K |
| 2021 | 0.00% | -359.80% | 0.49x | 0.00x | $-213.62K |
| 2022 | 0.00% | -85.72% | 0.53x | 0.00x | $-35.40K |
| 2023 | 0.00% | -158.77% | 1.02x | 0.00x | $-109.52K |
Industry Comparison
This section compares Sangui Biotech International Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sangui Biotech International Inc (SGBI) | $-1.05 Million | -29.52% | N/A | $36.51K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |